Product Code Database
Tecovirimat, sold under the brand name Tpoxx among others, is an Antiviral drug with activity against orthopoxviruses such as smallpox and monkeypox. In 2018 it was the first antipoxviral drug approved in the United States.
The drug works by blocking cellular transmission of orthopoxviruses, thus preventing disease.
Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from monkeypox and rabbitpox and causes no serious side effects in humans. Tecovirimat was first used for treatment in December 2018, after a laboratory-acquired vaccinia virus infection.
As of 2014 two million doses of tecovirimat were stockpiled in the US Strategic National Stockpile should an orthopoxvirus-based bioterrorism occur. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
In the European Union it is indicated for the treatment of smallpox, mpox, and cowpox. Tecovirimat can be taken by mouth and should be taken with a fatty meal. While tpoxx did not show efficacy against mpox in monotherapy in clincal setting, in vitro assays showed strong inhibition of both vaccinia and mpox in combination therapies.
Antimicrobial resistance to tecovirimat was described in vitro in cowpox virus during treatment already in 2005, prior to licensure. Since the global 2022–2023 mpox outbreak, resistance has been described with long treatment courses among severely immunocompromised persons, but also in people without prior treatment, suggesting human-to-human transmission. Tecovirimat resistance mutations identified in clinical MPXV isolates map to the VP37 dimer interface and prevent drug-induced dimerization.
A Diels–Alder reaction of cycloheptatriene with maleic anhydride forms the main ring system and then in the second step a reaction with 4-trifluormethylbenzhydrazide gives the cyclic imide of the drug.
As of 2008, it was permitted for phase II trials by the U.S. Food and Drug Administration (FDA). In phase I trials, tecovirimat was generally well tolerated with no serious adverse events. Due to its importance for biodefense, the FDA designated tecovirimat for fast-track status, creating a path for expedited FDA review and eventual regulatory approval. In July 2018, the FDA approved tecovirimat for the treatment of smallpox. the first antipoxviral drug approved in the United States.
In August 2022, the AIDS Clinical Trials Group (ACTG) began a randomized, placebo-controlled, double-blinded trial on the safety and efficacy of tecovirimat for mpox, known as STOMP (Study of Tecovirimat for Human mpox Virus), aiming to enroll at least 500 participants with acute mpox infection.
In December 2021, Health Canada approved oral tecovirimat for the treatment of smallpox in people weighing at least .
As of August 2022, Tpoxx was available in the US only through the Strategic National Stockpile as a Centers for Disease Control and Prevention investigational new drug. As of 2022, intravenous Tpoxx had no lower weight cap and can be used in under the investigational new drug protocol.
As of 2024, tecovirimat use in the US outside of a clinical trial should adhere to the CDC Investigational New Drug protocol in order to prevent mutations and to include surveillance to prevent spread of resistant virus.
History
Originally researched by the National Institute of Allergy and Infectious Diseases, the drug was owned by Viropharma and discovered in collaboration with scientists at the United States Army Medical Research Institute of Infectious Diseases. It is owned and manufactured by SIGA Technologies. SIGA and Viropharma were issued a patent for tecovirimat in 2012.
Clinical trials
As of 2009, the results of clinical trials supported its use against smallpox and other related orthopoxviruses. It showed potential for a variety of uses including preventive healthcare, as a post-exposure therapeutic, as a therapeutic, and an adjunct to vaccination.
Society and culture
Legal status
In November 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended to grant SIGA Technologies Netherlands B.V a marketing authorization under exceptional circumstances for tecovirimat, intended to treat orthopoxvirus disease (smallpox, mpox, cowpox, and vaccinia complications) in adults and in children who weigh at least Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Tecovirimat was approved for medical use in the European Union in January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
External links
|
|
